It's Not All About IO: Seven Drugs To Watch At ASCO
Executive Summary
Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago, including market-expanding data for Roche's Perjeta and J&J's Zytiga, and Phase III data for AstraZeneca's PARP inhibitor Lynparza in breast cancer.
You may also be interested in...
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
Oncology: Tissue-Agnostic Indications Advance Under US FDA's Breakthrough Umbrella
Merck's Keytruda may not be only oncologic with indication for cancer patients defined by molecular signature, not tissue of origin, for long: Ignyta's entrectinib and Loxo Oncology's larotrectinib are positioned for breakthrough-designated tissue-agnostic NDA submissions in NTRK fusion-positive cancers in 2018.